Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients
Clinical trial NCT02497131 · COMPLETED
Trial details
- NCT number
- NCT02497131
- Sponsor
- Fondazione Italiana Linfomi - ETS
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-09-21
- Primary completion
- 2019-09-24
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.